Anavex Life Sciences (AVXL) Proxy filing summary

Executive summary

• Definitive proxy materials filed for the 2026 Annual Meeting scheduled for September 24, 2026, with voting eligibility as of July 31, 2026.

• Board highlights decisive actions post-leadership transition, including appointing Dr. Terrie Kellmeyer as interim CEO and advancing clinical programs.

• Focus on progressing oral blarcamesine (ANAVEX®2-73) across three CNS indications and prioritizing FDA engagement for regulatory clarity.

• Board urges stockholders to vote for all six director nominees, emphasizing their qualifications and independence.

• PVG's attempt to gain control is criticized for lack of a clear plan and insufficient relevant expertise among its nominees.

Voting matters and shareholder proposals

• Stockholders are asked to vote for six director nominees on the WHITE proxy card.

• Board recommends voting against PVG’s nominees, citing lack of strategy and experience.

• PVG and its affiliates own only 0.35% of outstanding shares but seek effective control without offering a premium.

Board of directors and corporate governance

• Two new independent director candidates, Gautam Patel and Dr. Adrian Senderowicz, nominated to bring life sciences and capital markets expertise.

• If elected, half the Board will have been refreshed since the start of 2026, with all members being independent.

• Current Board includes experienced professionals in clinical, financial, and operational leadership roles.